Results suggest that it is important to develop interventions aimed at improving the quality of life in individuals with chronic migraine and to increase knowledge about headache and psychological consequences.
Many patients with spontaneous coronary artery dissection, particularly those with depression and with spontaneous coronary artery dissection-related chest pain, also have a history of migraine.
Peripheral nerve decompression surgery may be effective in reducing migraine headache frequency and intensity.
Vasodilation of the middle meningeal artery may occur at migraine onset on the pain side.
Treatment of cervicogenic headache with ultrasound-guided C2 nerve root coblation was associated with significant reductions in pain for at least 24 weeks.
Alcohol was a reported migraine trigger in 35.6% of participants, and approximately 25% of patients reported abstaining from alcohol because of its trigger effects.
Tosymra is an intranasal spray containing sumatriptan 10mg, a selective 5-HT1B/1D receptor agonist.
In patients with chronic migraine, monthly subcutaneous injections of galcanezumab at 120- and 240-mg doses were more effective than placebo for lowering the number of monthly migraine headache days.
Researchers assessed the efficacy and safety of lasmiditan (100 and 200 mg) to treat migraine.
Investigators observed that neutralizing antibodies exist in patients who have been receiving botulinum toxin therapies long-term and recommended neurologists try to use the smallest doses of botulinum toxin therapies possible to achieve a desired clinical outcome.
